Phase 1 of Bayer’s liver cancer plan is complete: Build a bridge between Stivarga and first-line blockbuster Nexavar.

Samsung won FDA nod for a Remicade biosim, Otsuka expanded anemia deal with Akebia, analysts are cautiously optimistic about China's foreign drug proposal…

BioMarin scored FDA backing for its orphan drug Brineura, now approved to treat the ultrarare CLN2 disease.

IP lawyers weigh in on what’s at stake in the Amgen v. Sandoz case heard at the Supreme Court on Wednesday.

Last quarter, Bristol-Myers Squibb walked back its 2017 guidance in a move some industry watchers attributed to Opdivo's recent setbacks. Q1 turned that…

Novartis is learning about its kickbacks punishment in South Korea as authorities decided to issue a fine of nearly $50 million.

Say what you want about AstraZeneca’s castoff strategy, but it helped drive another earnings beat for the lacking-in-sales drugmaker to kick off the year.

Drugmakers have been salivating at the prospect of tax reform since President Donald Trump won the election. But some would benefit far more than others.…

Every quarter, the FiercePharma team analyzes biopharma earnings reports and investor calls, and we're compiling the first quarter's here. Check back…

Pharma